Chimeric antigen receptor (CAR) T‐cell therapies have revolutionized the management of relapsed or refractory B‐cell acute lymphoblastic leukemia, CD19+ LPD, and MM. This evidence concerns the gene CD19 and Miyoshi myopathy.